New eye implant could replace daily glaucoma drops
NCT ID NCT07495852
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests a second-generation implant placed inside the eye that slowly releases travoprost, a drug that lowers eye pressure. The study will enroll 510 adults with open-angle glaucoma or high eye pressure. The goal is to see if the implant is safe and effective at controlling eye pressure over time, potentially reducing the need for daily eye drops.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Glaukos Investigative Site
RECRUITINGDothan, Alabama, 36301, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A sharper look at the retina: new imaging technology may spot eye disease earlier
- Eye surgery showdown: which drainage device placement saves more vision cells?
- Eye blood flow camera could spot glaucoma before vision fades
- Could a glaucoma eye drop also heal the cornea?
- Could a smartphone camera spot blinding eye diseases?
- Could stem cells restore sight in damaged eyes?